Current cancer drug targets
Aurora Kinases as Potential Therapeutic Targets for Tumors with pRB and/or MYCN Dysregulation.
Naheed Arfin Borah, Mamatha M Reddy
Published: 202610.2174/0115680096395779251022060212
Abstract
Dysregulation of signaling pathways facilitated by the RB1 tumor suppressor gene or the MYC family of oncogenes is often observed in various malignancies. Identifying drug targets for such cancers is challenging, as RB1 mutations are typically loss-o…
Preview only. Read the full abstract at the source